Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06004336 · ClinicalTrials.gov registry record · Phase 2
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
A Phase 2 study of Oligometastatic Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT06004336: Recruiting Phase 2 study of Oligometastatic Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT06004336 is a Phase 2 study of Oligometastatic Renal Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 144 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06004336, a Phase 2 study of Oligometastatic Renal Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- RADIATION Radiation therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
What NCT06004336 shows while recruiting
NCT06004336 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Oligometastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06004336 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06004336 about?
NCT06004336 is a clinical study titled "A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)". To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
What is the current status of trial NCT06004336?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2023-10-31. Estimated completion is 2029-01-01.
What conditions does trial NCT06004336 study?
This clinical trial studies the following conditions: Oligometastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT06004336?
The interventions under investigation include: Pembrolizumab (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT06004336?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06004336 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oligometastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06004336's enrollment target sits among peer trials
144 500th of 2000 higher than 1,495 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI